Nalmefene - TaiwanJ Pharmaceuticals

Drug Profile

Nalmefene - TaiwanJ Pharmaceuticals

Alternative Names: JKB-121; Nalmetrene - TaiwanJ Pharmaceuticals

Latest Information Update: 17 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jenken Biosciences
  • Developer Duke University Medical Center
  • Class Antidotes; Hepatoprotectants; Morphinans; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid receptor antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 11 Apr 2018 Efficacy and adverse events data from a phase II trial in Non-alcoholic steatohepatitis presented at the International Liver Congress (ILC-2018) (NCT02442687)
  • 29 Sep 2015 TaiwanJ Pharmaceuticals has patents pending for nalmefene in USA and other countries
  • 28 Sep 2015 Phase-I clinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) before September 2015 (TaiwanJ Pharmaceuticals Pipeline, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top